Krystal Biotech Inc - Asset Resilience Ratio
Krystal Biotech Inc (KRYS) has an Asset Resilience Ratio of 27.85% as of June 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See KRYS net working capital ratio to evaluate short-term liquidity relative to the company's equity base.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2017–2025)
This chart shows how Krystal Biotech Inc's Asset Resilience Ratio has changed over time. For the complete balance sheet picture, see Krystal Biotech Inc asset portfolio.
Liquid Assets Composition Over Time
This chart breaks down Krystal Biotech Inc's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. Explore KRYS long-term investment intensity to see how much of total assets are deployed in long-term investments.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $417.89 Million | 27.85% |
| Total Liquid Assets | $417.89 Million | 27.85% |
Asset Resilience Insights
- Very High Liquidity: Krystal Biotech Inc maintains exceptional liquid asset reserves at 27.85% of total assets.
- This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
- The company has significant short-term investments, indicating active treasury management.
Krystal Biotech Inc Industry Peers by Asset Resilience Ratio
Compare Krystal Biotech Inc's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
CSL Ltd
AU:CSL |
Biotechnology | 0.41% |
|
Vaxcyte Inc
NASDAQ:PCVX |
Biotechnology | 41.54% |
|
Bachem Holding AG
SW:BANB |
Biotechnology | 0.00% |
|
Definium Therapeutics, Inc.
NASDAQ:DFTX |
Biotechnology | 38.51% |
|
Chongqing Zhifei Bio Products
SHE:300122 |
Biotechnology | -0.08% |
|
HLB Co. Ltd
KQ:028300 |
Biotechnology | 3.29% |
|
Sinopep-Allsino Biopharmaceutical Co. Ltd. A
SHG:688076 |
Biotechnology | 2.30% |
|
Zhejiang Ausun Pharmaceutical Co Ltd
SHG:603229 |
Biotechnology | 0.12% |
Annual Asset Resilience Ratio for Krystal Biotech Inc (2017–2025)
The table below shows the annual Asset Resilience Ratio data for Krystal Biotech Inc.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 24.85% | $331.49 Million | $1.33 Billion | +0.92pp |
| 2024-12-31 | 23.93% | $252.65 Million | $1.06 Billion | +2.69pp |
| 2023-12-31 | 21.24% | $173.85 Million | $818.36 Million | -17.66pp |
| 2022-12-31 | 38.91% | $217.27 Million | $558.45 Million | +23.44pp |
| 2021-12-31 | 15.46% | $96.85 Million | $626.29 Million | +14.50pp |
| 2020-12-31 | 0.96% | $2.99 Million | $310.84 Million | -1.99pp |
| 2019-12-31 | 2.95% | $6.17 Million | $209.02 Million | -4.02pp |
| 2018-12-31 | 6.97% | $8.09 Million | $116.12 Million | -- |
| 2017-12-31 | 0.00% | $0.00 | $50.11 Million | -- |
About Krystal Biotech Inc
Krystal Biotech, Inc., a commercial-stage biotechnology company, discovers, develops, manufactures, and commercializes genetic medicines to treat diseases with high unmet medical needs in the United States. The company commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB). It also develops KB803 for ocular complications of dystro… Read more